{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:15:32Z","timestamp":1772608532418,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council","doi-asserted-by":"crossref","award":["RGPIN-2015-132"],"award-info":[{"award-number":["RGPIN-2015-132"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council","doi-asserted-by":"crossref","award":["STPGP-462995-14"],"award-info":[{"award-number":["STPGP-462995-14"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chair","doi-asserted-by":"crossref","award":["CRC-240394"],"award-info":[{"award-number":["CRC-240394"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.04.065","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T19:15:25Z","timestamp":1494270925000},"page":"3423-3430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics"],"prefix":"10.1016","volume":"35","author":[{"given":"Ernest","family":"Mili\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Julien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Biaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Venereo-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza P.","family":"Manceur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Ansorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Petiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rosa-Calatrava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Kamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.065_b0005","unstructured":"Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA et al. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States, n.d. <https:\/\/www.cdc.gov\/flu\/about\/disease\/2015-16.htm>."},{"key":"10.1016\/j.vaccine.2017.04.065_b0010","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.vaccine.2009.02.064","article-title":"Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.vaccine.2012.10.111","article-title":"Global production capacity of seasonal influenza vaccine in 2011","volume":"31","author":"Partridge","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.04.065_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.8.1.18859","article-title":"New technologies for influenza vaccines","volume":"8","author":"Dormitzer","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.065_b0030","first-page":"823","article-title":"Influenza cell-culture vaccine production","volume":"vol. 2","author":"Hilleringmann","year":"2014"},{"key":"10.1016\/j.vaccine.2017.04.065_b0035","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/504831","article-title":"Current and emerging cell culture manufacturing technologies for influenza vaccines","author":"Mili\u00e1n","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2017.04.065_b0040","unstructured":"WHO Global Influenza Programme. Report of a WHO Informal Consultation held in Geneva, Switzerland Influenza Vaccine Response during the Start of a Pandemic Influenza Vaccine Response during the Start of a Pandemic; 2015."},{"key":"10.1016\/j.vaccine.2017.04.065_b0045","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0050","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.96.16.9345","article-title":"Generation of influenza A viruses entirely from cloned cDNAs","volume":"96","author":"Neumann","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2017.04.065_b0055","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","volume":"97","author":"Hoffmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.04.065_b0060","unstructured":"WHO. Process of influenza vaccine virus selection and development. World Heal Organ; 2007. p. 1\u201311."},{"key":"10.1016\/j.vaccine.2017.04.065_b0065","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1016\/S0264-410X(02)00268-2","article-title":"Eight-plasmid system for rapid generation of influenza virus vaccines","volume":"20","author":"Hoffmann","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0070","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1099\/0022-1317-81-12-2843","article-title":"Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids","volume":"81","author":"Hoffmann","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jviromet.2013.09.007","article-title":"Vero\/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds","volume":"196","author":"Medina","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.04.065_b0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virusres.2004.02.028","article-title":"Efficient generation and growth of influenza virus A\/PR\/8\/34 from eight cDNA fragments","volume":"103","author":"De Wit","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.04.065_b0085","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","article-title":"A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor","volume":"28","author":"Lohr","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0090","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2015.06.110","article-title":"Cell substrates for the production of viral vaccines","volume":"33","author":"Aubrit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jviromet.2007.03.014","article-title":"Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells","volume":"144","author":"Durocher","year":"2007","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.04.065_b0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jviromet.2013.10.038","article-title":"Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery","volume":"196","author":"Chahal","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.04.065_b0105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bit.21467","article-title":"Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification","volume":"98","author":"Segura","year":"2007","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.04.065_b0110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2007.10.017","article-title":"Development of a suspension serum-free helper-dependent adenovirus production system and assessment of co-infection conditions","volume":"148","author":"Meneses-Acosta","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.04.065_b0115","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/bit.22113","article-title":"An efficient and scalable process for helper-dependent adenoviral vector production using polyethylenimine-adenofection","volume":"102","author":"Dormond","year":"2009","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.04.065_b0120","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1016\/j.vaccine.2010.03.029","article-title":"Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing","volume":"28","author":"Le Ru","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virol.2011.03.011","article-title":"Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles","volume":"414","author":"Moul\u00e8s","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.04.065_b0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jviromet.2008.03.006","article-title":"Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca\/ts phenotype","volume":"150","author":"Mo","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.04.065_b0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nprot.2009.200","article-title":"A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide","volume":"5","author":"Li","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2017.04.065_b0140","first-page":"5","article-title":"Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays","author":"Gravel","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2017.04.065_b0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12896-015-0152-x","article-title":"Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0150","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.vaccine.2016.04.089","article-title":"Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: an effective influenza vaccine candidate","volume":"34","author":"Venereo-sanchez","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0155","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1021\/jp211845t","article-title":"Modeling elastic pore sensors for quantitative single particle sizing","volume":"116","author":"Kozak","year":"2012","journal-title":"J Phys Chem C"},{"key":"10.1016\/j.vaccine.2017.04.065_b0160","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1021\/ac200195n","article-title":"Quantitative sizing of nano\/microparticles with a tunable elastomeric pore sensor","volume":"83","author":"Vogel","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.vaccine.2017.04.065_b0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vaccine.2014.11.027","article-title":"Particle quantification of influenza viruses by high performance liquid chromatography","volume":"33","author":"Transfiguracion","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0166-0934(87)90005-X","article-title":"Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids","volume":"16","author":"Alain","year":"1987","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.04.065_b0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1008000327766","article-title":"Transient gene expression in mammalian cells grown in serum-free suspension culture","volume":"30","author":"Schlaeger","year":"1999","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2017.04.065_b0180","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jbiotec.2013.05.001","article-title":"Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium","volume":"166","author":"Cervera","year":"2013","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0185","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/30.2.e9","article-title":"High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells","volume":"30","author":"Durocher","year":"2002","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.vaccine.2017.04.065_b0190","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/bit.10774","article-title":"Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency","volume":"84","author":"Pham","year":"2003","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.04.065_b0195","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jgm.1370","article-title":"Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures","volume":"11","author":"Ansorge","year":"2009","journal-title":"J Gene Med"},{"key":"10.1016\/j.vaccine.2017.04.065_b0200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1743-422X-10-141","article-title":"Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches","volume":"10","author":"Thompson","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2017.04.065_b0205","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1472-6750-11-84","article-title":"Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture","volume":"11","author":"Petiot","year":"2011","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0210","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1016\/j.vaccine.2015.07.104","article-title":"Critical review of current and emerging quantification methods for the development of influenza vaccine candidates","volume":"33","author":"Manceur","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0215","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1016\/j.vaccine.2015.06.090","article-title":"Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1\u20133 April 2014","volume":"33","author":"Ampofo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.065_b0220","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1099\/jgv.0.000457","article-title":"Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses","volume":"97","author":"Parker","year":"2016","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0225","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","article-title":"The production of hemagglutinin-based virus-like particles in plants : a rapid, efficient and safe response to pandemic influenza","volume":"8","author":"Aoust","year":"2010","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.vaccine.2017.04.065_b0230","doi-asserted-by":"crossref","first-page":"e15559","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"Landry","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.065_b0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1750-2659.2006.00007.x","article-title":"Production of a novel influenza vaccine using insect cells: protection against drifted strains","volume":"1","author":"Cox","year":"2007","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2017.04.065_b0240","first-page":"107","article-title":"A fast track influenza virus vaccine produced in insect cells","author":"Cox","year":"2011","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.vaccine.2017.04.065_b0245","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T23:10:45Z","timestamp":1549753845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":49,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17305571"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}